IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($1.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82), Zacks reports. The business had revenue of $7.00 million during the quarter, compared to the consensus estimate of $7.00 million.
NASDAQ IDYA traded up $0.24 on Friday, reaching $21.00. The stock had a trading volume of 1,427,577 shares, compared to its average volume of 787,501. IDEAYA Biosciences has a 12-month low of $20.63 and a 12-month high of $47.74. The business's 50-day moving average price is $24.36 and its 200 day moving average price is $29.97. The stock has a market cap of $1.82 billion, a P/E ratio of -9.01 and a beta of 0.82.
Several research firms have recently commented on IDYA. Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. UBS Group began coverage on IDEAYA Biosciences in a report on Thursday, October 24th. They set a "buy" rating and a $50.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Leerink Partners lowered IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $41.00 to $27.00 in a report on Tuesday, November 5th. Finally, Wedbush reiterated an "outperform" rating and set a $52.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $53.58.
View Our Latest Report on IDEAYA Biosciences
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider IDEAYA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.
While IDEAYA Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.